Empower Clinics Encouraged by US Drug Enforcement Administration’s (DEA) Decision on CBD-based Treatment

SEATTLE–(BUSINESS WIRE)–Empower Clinics Inc. (OTC: EPWCF; CSE: EPW; FRA 8EC), a leading owner and operator of medical cannabis and wellness clinics in the US, today issued a statement regarding the US Department of Justice and Drug Enforcement Agency’s (DEA) decision late last week to place a cannabidiol (CBD)-based treatment, Epidiolex, in schedule V of the Controlled Substances Act (CSA), the least restrictive schedule of the CSA.

In June, the Food and Drug Administration (FDA) announced that it approved Epidiolex for treating two severe form of epilepsy. Epidiolex is the first FDA-approved drug to contain CBD.

“We are very encouraged by this move, as we believe it will set the stage for potentially more Federally approved medications with CBD,” said Craig Snyder, Empower CEO. “We are prepared to launch our company’s own base of branded CBD products in the very near future and are pleased to see a greater openness at both state and Federal levels to the considerable benefits associated with CBD.”

According to Snyder, Empower’s products will specifically target common medical conditions involving pain, sleep, stress, and digestion. The products, to be available as tinctures or topical creams, are non-THC CBD, meaning that they are non-psychotropic: they do not directly affect mood, perception, or consciousness.

ABOUT EMPOWER

Empower is a leading owner and operator of medical cannabis and wellness clinics, as well as a developer of medical products in the US, focused on enabling individuals to improve and protect their health. The company provides treatment solutions through its physician-staffed clinics that are focused on education, data, and efficacy. Empower is a recognized leader and the first choice for patients seeking quality experience and improved health.

For further information about Empower please see the Company’s website at www.empowerclinics.com.

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. Forward-looking information contained in this news release includes, but is not limited to, the delisting of the Common Shares from the TSXV, the listing of the Common Shares on the CSE and the future growth plans of the Company. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events and are therefore based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.

Neither the TSXV, the CSE nor their Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Contacts

For Empower Clinics Inc.
Investors:
Boom Capital Markets
Steve Low, 647-620-5101
steve@boomcapitalmarkets.com
or
Press:
Mark Peterson, 206-390-0204
Mark@pointerpr.com

By |2018-10-11T21:59:02+00:00October 1st, 2018|CBD, Legislation, News, Press|
Empower Clinics Inc.
Exchange: CSE
Symbol: EPW
Last Price: 0.23
Change: -0.05
Volume: 158021
Last Updated: 10/22/2018 02:23:44 PM EST
GDPR Compliance Notice: This site uses cookies and third party tracking scripts to help us improve your website and shopping experience. By continuing to browse our website you are agreeing to our cookie and privacy policies. View Our Privacy Policy Continue